Assertio (ASRT)
(Delayed Data from NSDQ)
$1.30 USD
-0.05 (-3.70%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.29 -0.01 (-0.77%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ASRT 1.30 -0.05(-3.70%)
Will ASRT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ASRT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASRT
Assertio (ASRT) Reports Q2 Loss, Tops Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
ASRT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Assertio (ASRT) Q2 Earnings Expected to Decline
Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?
Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why
Other News for ASRT
Assertio Holdings: Management Change Could Improve Comeback Chances
Assertio to Participate in the HC Wainwright and Lake Street Conferences in New York City September 10-12, 2024
Assertio Therapeutics: Strong Buy Rating on Robust Portfolio and Strategic Growth
Assertio Holdings management to meet virtually with Lake Street
Assertio Holdings management to meet virtually with Lake Street